Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity

This study has been completed.

Study NCT00166205 Information provided by Ethicon Endo-Surgery

First Received: September 9, 2005 Last Updated: January 23, 2009 History of Changes

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Condition:	Obesity, Morbid
Intervention:	Device: Swedish Adjustable Gastric Band

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Swedish Adjustable Gastric Band (SAGB)	No text entered.

Baseline Measures

	Swedish Adjustable Gastric Band (SAGB)
Number of Participants [units: participants]	276
Age [units: participants]
<=18 years	0
Between 18 and 65 years	276
>=65 years	0
Age [units: years] Mean ± Standard Deviation	38.6 ± 9.4
Gender [units: participants]
Female	216
Male	60
Region of Enrollment [units: participants]
United States	276
Mean Excess Body Weight^[1] [units: Pounds] Mean ± Standard Deviation	130.0 ± 33.1

[1]	Excess weight is computed as baseline weight minus Ideal weight. Ideal weight as provided in the 1983 Metropolitan Life Height and Weight Table using the upper limit of the midpoint range.

Outcome Measures

Show All Outcome Measures

1. Primary:

Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB) [ 3 years ]

Show Outcome Measure 1

2. Primary:

Percent Excess Weight Loss [ 3 Years Post Operative ]

Show Outcome Measure 2

3. Secondary:

Changes in Excess Body Weight (EBW) [ 3 years ]

Show Outcome Measure 3

4. Secondary:

Changes in Body Mass Index (BMI) [ 3 years ]

Show Outcome Measure 4

5. Secondary:

Change in Absolute Weight [ 3 years ]

Show Outcome Measure 5

6. Secondary:

Changes in Quality of Life (QOL) Measures [ 3 years ]

Show Outcome Measure 6

7. Secondary:

Changes in Glycosylated Hemoglobin (HbA1c) [ 3 years ]

Show Outcome Measure 7

8. Secondary:

Number of All Adverse Events of Subjects Implanted With the SAGB [ 3 Years ]

Show Outcome Measure 8

9. Secondary:

Changes in High Density Lipoproteins (HDL) [ 3 year ]

Show Outcome Measure 9

10. Secondary:

Changes in Low Density Lipoproteins (LDL) [ 3 years ]

Show Outcome Measure 10

11. Secondary:

Changes in Total Cholesterol [ 3 years ]

Show Outcome Measure 11

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The PI shall have the right to publish the results of research to include in any publication. The PI will provide the Sponsor with at least sixty (60) days for review of a manuscript. No paper that incorporates Sponsor Confidential Information will be submitted for publication without Sponsor's prior written agreement.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Sheryl Helsinger, Director
Organization: Worldwide Clinical Operations
phone: 513-337-3079
e-mail: shelsing@its.jnj.com

No publications provided

Responsible Party:	Clinical Operations ( Sheryl Helsinger, Director )
Study ID Numbers:	CI-02-0006
Study First Received:	September 9, 2005
Results First Received:	October 21, 2008
Last Updated:	January 23, 2009
ClinicalTrials.gov Identifier:	NCT00166205 History of Changes
Health Authority:	United States: Food and Drug Administration